The words hit me like a punch in the stomach. I felt all the blood drain from my face and the air seep out of my lungs. Until ...

Without revealing specific details, GSK announced that it is terminating the development of its investigational herpes ...

A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine candidate failed to meet its primary efficacy endpoint.

Caused mainly by herpes simplex virus type 2 (HSV-2), the disease is characterized by recurrent outbreaks in which the ...

GSK has announced that Part II of the Phase I/II TH HSV REC-003 trial of its therapeutic herpes simplex virus (HSV) vaccine ...

British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...

GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in ...

GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

While they can heal naturally, preventing a fever blister from recurring should be a priority for anyone who has experienced ...